Bull&Bear | Summit Therapeutics Leads Bullish Surge with 55.99% Gain, Rezolve AI Falls 18.49%

In the realm of bullish stocks:

Summit Therapeutics (SMMT) saw a remarkable increase of 55.99%. The company has made significant progress in its cancer drug development.

Instil Bio (TIL) surged by 54.32%, continuing its upward trend over the past two days, accumulating a 55.41% rise. HC Wainwright & Co. has maintained a buy rating on Instil Bio and raised the target price to $25.

Relay Therapeutics (RLAY) climbed 52.40%. Goldman Sachs upgraded Relay Therapeutics to a buy rating, setting a target price of $20.

Applied Digital (APLD) increased by 44.62%. Needham maintained a buy rating on Applied Digital with a target price of $11.

Bridger Aerospace (BAER) gained 41.24%. Canaccord Genuity maintained a buy rating on Bridger Aerospace, sustaining the target price at $5.25.

In the realm of bearish stocks:

Rezolve AI (RZLV) dropped 18.49%. According to a filing with the U.S. Securities and Exchange Commission, Igor Lichagov reported holding a 21.14% stake in Rezolve AI Limited as of August 15.

Tango Therapeutics (TNGX) fell by 15.89%, marking a consecutive two-day decline of 21.58%. Although Tango Therapeutics' stock had previously risen by 29%, its business performance has yet to catch up.

Kewaunee Scientific (KEQU) decreased by 15.13%. The stock showed intraday volatility and significantly dropped by 6.16% in the afternoon trade to $46.50.

Trinseo (TSE) fell by 13.56%. Jefferies revised down the target price of Trinseo PLC from $3.85 to $2.5.

Absci (ABSI) dropped 12.94%, extending its two-day loss to 15.25%. Absci Corporation reported a net profit of -$24.75 million for the second quarter of fiscal year 2024, which is a 40.60% improvement compared to the previous year.